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Abstract Combinations of KIR and HLA genes associate
with pregnancy complications as well as with many other
clinical scenarios. Understanding how certain KIR and HLA
genes influence the biology of a disease is, however, a formi-
dable challenge. These are the twomost variable gene families
in the human genome. Moreover, the biology of a disease is
best understood by studying the cells of the affected tissue.
Natural Killer (NK) cells express KIR and are the most abun-
dant leukocytes in the uterus. Most of our knowledge of NK
cells is based on what we have learned from cells isolated
from blood, but these are different from their tissue resident
counterparts, including uterine NK (uNK) cells. Reproductive
immunology faces an additional challenge: Two genotypes
must be considered because both maternal and foetal HLA
class I molecules may influence the outcome of pregnancy,
most likely through interactions with maternal KIR expressed
on uNK cells. Maternal uNK cells are not spontaneously cy-
totoxic and instead engage in interactions with trophoblast.
We hypothesise that these interactions regulate allocation of
resources between the foetus and the mother and may go
wrong in diseases of pregnancy.
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Introduction
More than 10% of the global burden of disease is due to
pregnancy complications of mother and child (WHO 2004).
Association of KIR and HLA variants with pregnancy compli-
cations, including recurrent miscarriage and the gestation-
specific hypertensive disorder pre-eclampsia, suggests that
these genes may have a role in these conditions. This review
aims to illustrate the difficulties in drawing a coherent picture
that ties together the genetic evidence with the biology of
uterine NK (uNK) cells. One may intuitively expect the ma-
ternal immune system to be suppressed during pregnancy to
achieve tolerance to paternal antigens. This long-held view is
rooted in the misleading analogy of placental implantation
with organ transplantation (Colucci and Kieckbusch 2015).
Recent evidence, however, shows that the maternal immune
system is not all suppressed during pregnancy, and that some
responses are even strengthened (Kraus et al. 2012). For ex-
ample, NK and T cell responses to influenza are enhanced in
pregnant women (Kay et al. 2014). Because maternal uterine
NK cells (uNK) are the most abundant lymphocytes in the
decidua and because they act as killer cells in the periphery,
one view is that maternal uNK cells may ‘kill’ the foetus.
Although popular, this view is most likely incorrect (Moffett
and Shreeve 2015). Uterine NK cells, as well as other tissue
resident NK cells, are poorly cytotoxic and only directly con-
tact the trophoblast (immature placenta), not the foetus.
Nevertheless, one of the first questions arising when one
thinks of the immunogenetics of reproduction is almost inev-
itably: ‘Why does the mother not reject the foetus?’This is
indeed an extraordinary paradox because like cancer cells,
the foetal trophoblast cells invade deep into maternal uterine
tissue, which is half-mismatched to the foetus and full of ma-
ternal NK cells (normally known for their propensity to kill
cancer cells). But maternal uNK cells are not spontaneously
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cytotoxic and instead engage in a molecular conversation with
trophoblast. Our hypothesis is that this interaction is not a
conflict but a compromise that allows allocation of resources
between the foetus and the mother and somehow goes wrong
in diseases of pregnancy (Moffett and Colucci 2015).
At the maternal-foetal boundary, trophoblast invades into
maternal arteries to transform them into high conductance
vessels (Fig. 1). This arterial transformation by trophoblast is
essential for normal foetal growth. Trophoblast is inherently
highly invasive and is regulated by uNK cells. Only
extravillous trophoblast (EVT) express selective HLA class I
molecules, with all other trophoblast cell types being devoid
of HLA expression. EVT differentiate from trophoblast pro-
genitors, invade deep into the uterine wall and interact with
maternal immune cells, including uNK cells and monocytes.
EVT express a maternal and a paternal HLA-C allotype (King
et al. 2000) as well as HLA-E, HLA-G (Apps et al. 2008,
2009) and possibly HLA-F (Hackmon et al. 2017), but not
polymorphic HLA-A nor HLA-B. HLA-C is, therefore, the
only highly polymorphic HLAmolecule expressed by tropho-
blast. Inhibitory and activating KIR on uNK cells bind to
HLA-C on foetal trophoblast cells. Together with intrauterine
foetal growth restriction (FGR), preterm labour and late spon-
taneous abortion, pre-eclampsia forms part of the great obstet-
rical syndromes (GOS), which are characterised by failure of
placentation (Brosens et al. 2011). Based on genetic studies
and more recent evidence in mouse models (reviewed in
(Moffett and Colucci 2014), we hypothesise that excessive
inhibition of uNK cells impedes trophoblast invasion leading
to reduced blood flow. This ultimately reduces oxygen and
nutrient delivery to the foetus and serves as the catalyst for
placental stress, pre-eclampsia and low birth weight. At the
opposite end of the spectrum, strong activation of uNK cells
leads to macrosomia, obstructed labour and post-partum
haemorrhage (Moffett and Colucci 2015), where most mater-
nal and neonatal mortality occurrence is at the two extremes of
birth weight (Fig. 1). How does this tie in with the role of KIR
and HLA in NK cell biology?
Combinations of KIR and HLA genes associate with preg-
nancy complications as well as many other clinical scenarios
including cell transplantation, HIV progression to AIDS, res-
olution of HCV and some malignancies (Beziat et al. 2017).
Understanding how certain KIR and HLA genes influence the
biology of a disease is, however, a formidable challenge.
These are the two most variable gene families in the human
genome. Perhaps not surprisingly, and like for other disease
associations with KIR and HLA genes, there is a lack of con-
sensus, and some reports are even conflicting. Several reasons
may explain the controversies, and many have been discussed
before (Khakoo and Carrington 2006; Hammond et al. 2016),
including some inherent to the complexity of the KIR-HLA
system and its extreme variability across individuals and pop-
ulations. Other factors contributing to the lack of a coherent
picture may relate to differences in sample sizes, populations
studied or methodologies. Moreover, the biology of a disease
is best understood by studying the cells of the affected tissue.
Most of our knowledge of NK cells is based on what we have
learned from cells isolated from blood. It is now clear that
blood NK cells are different from their tissue resident coun-
terparts (Bjorkstrom et al. 2016), including those found in the
uterine decidua (Koopman et al. 2003). Reproductive immu-
nology faces an additional challenge; two genotypes must be
considered because both maternal and foetal HLA may influ-
ence the outcome of pregnancy, most likely through interac-
tions with maternal KIR expressed on uNK cells.
Generation of compound KIR and HLA diversity
KIR genes encode for either inhibitory or activating receptors
expressed on NK cells and small subsets of T cells. The ex-
cellent review by Beziat et al., includes more information
(Beziat et al. 2017). KIR diversity is generated at many levels.
Due to their head-to-tail positioning on the KIR locus (within
the leukocyte receptor complex, LRC, on 19q13.4), and the
sequence similarity, KIRs are prone to undergo non-allelic
homologous recombination, which generates diversity by
contraction and expansion of the KIR locus (Traherne et al.
2010). This probably explains why KIR haplotypes are poly-
genic. In addition, each KIR gene has roughly 5 to 50 alleles.
The synergy between haplotype and allelic diversity makes it
unlikely for unrelated individuals to share the same KIR ge-
notype. KIR haplotypes can be broadly grouped into A and B
haplotypes according to their gene content. Almost all haplo-
types share framework genes KIR3DL3, KIR3DP1 (a
pseudogene),KIR2DL4 and KIR3DL2. KIR2DL4 is a peculiar
KIR because it has one inhibitory motif in its intracellular tail,
but, unique among the ‘L’ KIR, it can also pair with the FcγR
adaptor to activate tyrosine kinases and trigger NK cell acti-
vation (Kikuchi-Maki et al. 2005). KIR2DL4 is not expressed
on the surface of peripheral NK cells but the gene is conserved
between humans and primates, and the receptor is thought to
be found within all NK cells. There are also null alleles of
KIR2DL4. KIR A haplotypes have a fixed number of seven
genes, with two activating but often non-functional KIR
(KIR2DL4 and KIR2DS4). Eighty percent of Caucasians have
a mutation that prevents KIR2DS4 functions. Thus, most
Caucasians with a KIR AA genotype have no activating KIR
on the surface of NK cells. KIR B haplotypes have a variable
number of genes, from four to 15 and usually at least two or
more activating, functional receptors (Jiang et al. 2012).
Activating receptors on the KIR B include KIR2DS1,
KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1. Due to the
presence of recombination hot spot, a centromeric (cen) and
a telomeric (tel) end of the KIR locus are identifiable, with
various combinations of cen-A, cen-B, tel-A and tel-B parts of
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the haplotype. For convention, KIR haplotypes made by cen-
A and tel-A are defined as KIR A haplotype, whereas the
combinations of cen-A/tel-B and cen-B/tel-A are defined as
KIR B haplotype along with cen-B/tel-B. Despite variations
in frequencies across populations, both haplotypes are found
in all populations, suggesting balancing selection (Parham and
Moffett 2013). Indeed, certain KIR and HLA variants may
have been selected under the pressure of both pathogens and
reproduction (Penman et al. 2016). VariableKIR gene content,
allelic polymorphism and cell surface expression of both KIR
and HLA individual alleles, as well as different KIR-HLA
binding strengths and intracellular KIR signal strength coa-
lesce to generate extreme diversity (Fig. 2). In addition, KIR
are expressed by subsets of NK cells, and the variegated ex-
pression makes it difficult to infer the biological significance
of association between KIR and diseases. Furthermore, the
strong linkage disequilibrium among some KIR (i.e.
KIR2DL2 and KIR2DS2 or KIR2DS1 and KIR3DS1) makes
it hard to isolate the role of individual KIRs.
Although KIR and HLA genes segregate independently on
chromosomes 19 and 6, respectively, KIR expressed on NK cells
bind polymorphic HLA class I molecules and their interactions
regulate NK cell biology (Parham and Moffett 2013). The spec-
ificity of KIR binding to HLA class I molecules is determined by
residues 76–83 within the α1 helix of the HLA class I heavy
chain. These residues make up four epitopes recognized by KIR.
HLA-C allotypes carry either the C1 or the C2 epitope and all
HLA-C allotypes are KIR ligands. Only subsets of HLA-A and
HLA-B allotypes, however, bind to KIR. The HLA-A*03 and
HLA-A*11 allotypes carry the A3/11 epitope and some HLA-A
and HLA-B allotypes carry the Bw4 epitope. In addition, some
HLA-B allotypes carry the C1 epitopes. These four epitopes bind
different subsets of inhibitory KIR. Among inhibitory receptors,
KIR2DL1 binds the C2 epitope, KIR2DL2/3 binds the C1 epi-
tope, and KIR3DL1 binds the Bw4 epitope. Among activating
receptors, KIR2DS1 binds the C2 epitope, and KIR3DS1 binds
the Bw4 epitope. The binding strength of inhibitory receptors is
superior to that of activating receptors to the same epitope.
Binding to the A3/11 epitope appears to be dependent on pep-
tides. Unusual ligands are HLA-G, which is bound by
KIR2DL4, and open conformers of HLA-F, which seem to be
bound by KIR3DS1. NK cells are sensitive to the levels of HLA
ligands (Hilton et al. 2012; Moesta et al. 2008), and both indi-
vidual KIR and HLA alleles show differential levels of expres-
sion (Thomas et al. 2009), and these interactions may contribute
to disease associations differently (Beziat et al. 2017).
KIR and HLA influence NK cells
The interactions between KIR and HLA class I molecules
regulate NK cells in at least two ways (Fig. 2). One is
Fig. 1 Interactions between uNK cells and trophoblast regulate
allocation of resources at the maternal-foetal interface. Extra-Villous
Trophoblast (EVT, green) transforms the uterine arteries into large
conduits. Maternal uNK cells regulate trophoblast invasion. Inhibitory
and activating KIR, in combination with HLA-C variants on the EVT,
regulates uNK cell functions. Too much inhibition (yellow area)
correlates with shallow trophoblast invasion and low birth weight,
whereas toomuch activation (blue area) correlates with high birth weight.
Mortality ofmother and child (brown curve) occurs at the two extremes of
birth weight (blue curve). Adapted from Hiby et al. (2014), J Immunol,
192, 5069–5073
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straightforward and operates during an immune response
when inhibitory KIR suppress, and activating KIR elicit, cy-
tokine production and/or cytotoxicity by subsets of NK cells.
During a response, the lack of engagement of inhibitory KIR
by the cognate HLA ligands facilitates NK cell activation
through Bmissing-self’ recognition, that is when HLA class I
molecules are downregulated following a viral infection or
tumour transformation. The other way KIR and HLA interac-
tions influence NK cells is through NK cell education, which
occurs during NK cell resting state and throughout the life of
an individual (Fig. 2). NK cell education is thought to be the
result of the continuousKIR and HLA interactions, away from
an immune response and modifiable by the tissue microenvi-
ronment. Although the process is not fully understood molec-
ularly, its outcome is quantifiable and predictable and based
on the individual’s inherited KIR andHLAvariants. For exam-
ple, the subset of KIR2DL1+ NK cells in an individual carry-
ing a C2+ HLA-C allotype will respond more vigorously in
assays that measure either cell cytotoxicity (typically killing of
K562 erythroleukaemia targets), degranulation (by flow cy-
tometry assessment of CD107a expression) or cytokine pro-
duction (IFN-γ, MIP-1α, GM-CSF) upon NK cell activation
through either co-incubation with targets or crosslinking of
activating receptors. These assays may not reflect the true—
and indeed poorly understood—in vivo functions of uNK
cells; however, they are useful as a ‘proxy’ to quantify uNK
cell activation (Sharkey et al. 2015). Although the ligands for
most activating KIR are unknown, activating KIR2DS1 also
binds C2+ HLA-C allotypes. The continuous interactions be-
tween KIR2DS1 and self C2+ HLA-C molecules in resting
state, however, leads to hypo responsiveness, so that the sub-
set of KIR2DS1+ NK cells will be educated to be anergic in
individuals who carry C2+HLA-C allotypes, perhaps to avoid
autoimmunity (Fig. 2). Other receptors influence NK cells.
For example, the conserved and non-variable CD94/NKG2A
inhibitory receptor can both educate NK cells and suppress
their functions upon binding to the non-classical class I HLA-
E molecules. NK cell education is thought to form the basis of
NK cell tolerance and to shape the repertoire of NK cells.
Exposure of NK cells to cytokines produced during an im-
mune response may however activate all NK cell subsets,
educated or not, making it hard to understand the exact role
of NK cell education in pathophysiology.
Role of KIR and HLA during immune responses
and in resting state (NK cell education)
The most parsimonious model to infer the role of KIR and
HLA interactions from disease association studies relates to
NK cell responses rather than NK cell education. In other
words, and put simply, KIR A haplotypes are mostly inhibito-
ry and KIR B haplotypes are mostly activating. The associa-
tion of a condition with KIR A haplotype or with a given
inhibitory KIR indicates that excessive inhibition of NK cells
contributes to the pathogenesis of the disease. For example,
the strongly inhibiting KIR2DL2 and its C1+ HLA-C ligands
were overrepresented in a cohort of 685 patients with persis-
tent hepatitis C (HCV) infection, as compared with 352 indi-
viduals who resolved the infection (Khakoo et al. 2004). The
latter instead had an increased frequency of the weakly
inhibiting KIR2DL3. The finding suggested that weak inhibi-
tion of NK cells in the liver leads to beneficial immune re-
sponses and the resolution of infection. On the other hand,
strong inhibition of NK cells may prevent immunopathology.
In line with this, KIR2DL3 may predispose to lethal cerebral
malaria, presumably because it does not sufficiently refrain
immune responses against the pathogen (Hirayasu et al.
Fig. 2 How do diverse KIR and HLA interactions influence NK cell
functions? Combination of KIR and HLA variants generate diversity at
many levels. Interactions of inhibitory KIR with their ligands in resting
state educate NK cells. Counter-intuitively, inhibitory KIR prime
funct ional competence, while act ivating KIR make cel ls
hyporesponsive. During an immune response, or at the maternal-foetal
interface, inhibitory KIR may suppress, and activating KIR elicit NK cell
functions
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2012). At the other end of the spectrum, activating KIR are
associated with disease resistance. For example, KIR3DS1 is
associated with both slower progression to AIDS (Martin et al.
2002) and clearance of HCV (Khakoo et al. 2004). Donor KIR
B haplotype is associated with better outcome following
haploidentical haematopoietic stem cell transplantation in pa-
tients with acute myeloid leukaemia (Cooley et al. 2009).
Although the biological role of NK cell education is not
fully understood, it is compatible with the interpretation of
some association studies. The idea is that interactions between
strong inhibitory KIR and self HLA class I molecules in rest-
ing state shape a functionally competent NK cell repertoire
capable of responding to viral infections that cause
downmodulation of the same HLA class I molecules.
Examples of inhibitory receptors implicated in disease resis-
tance are the association of KIR3DL1 and Bw4+ allotypes
with slow AIDS progression and lower viral load in a cohort
of over 1500 HIV+ individuals (Martin et al. 2007). This
finding is in apparent contradiction with the one described
earlier of association between activating KIR3DS1 and resis-
tance to progression to AIDS. The model proposed suggests
that interactions between inhibitory KIR3DL1 and Bw4+ al-
lotypes during resting state shape a repertoire of NK cell sub-
sets capable of springing into vigorous action when, during
infections, the inhibition is lost due to down regulation of
MHC class I molecules. At the other end of the spectrum of
NK cell education, we find examples of disease associations
with activating KIR. For example, in haematopoietic stem cell
transplantation, the presence of an activating donor KIR,
mostly KIR2DS1, correlates with better outcome (Cooley
et al. 2009). However, if the donor also carries a C2+ HLA-
C allotype, the beneficial effect of KIR2DS1 is lost, and this is
thought to be due to induction of hyporesponsiveness in the
KIR2DS1+ NK cell subset (Pittari et al. 2013).
KIR and HLA association with recurrent
miscarriage
Recurrent Miscarriage (RM), also referred to as recurrent
spontaneous abortion or recurrent pregnancy loss, is the oc-
currence of three or more consecutive miscarriages with no
live birth (Rai and Regan 2006). About 1% couples experi-
ence RM, with the majority of cases being unexplained and
some possibly due to immune aetiology (Jauniaux et al. 2006).
The lack of HLA-A and HLA-B on EVT makes it unlikely
that they interact with maternal T cells. There is no evidence
that human Tcells reject the foetus, although elegant studies in
transgenic mouse models have shown the importance of reg-
ulatory T cells in preventing abortion (reviewed in (Ruocco
et al. 2014), and regulatory T cells have also been described in
HLA-C mismatched human pregnancies (Tilburgs et al.
2009). Because of the variability of KIR and HLA genes,
every pregnancy will have a unique KIR and HLA-C combi-
nation. This combined with the fact that uNK cells interact
directly with trophoblast, suggests that KIR and HLA may
play a role in RM. Studies of association between KIR and
HLAvariants and RM are particularly conflicting. Some of the
initial studies reported associations of RM with reduced fre-
quency of inhibitory KIR (Varla-Leftherioti et al. 2003; Flores
et al. 2007), or with increased frequency of activating KIR
(Vargas et al. 2009; Ozturk et al. 2012) or no association at
all (Witt et al. 2004). Assessing association with KIR genes
only is not sufficient. Maternal KIR and HLA class I variants,
as well as paternal HLA-C variants, must be considered to-
gether to appreciate the full complexity of the system (Chazara
et al. 2011). Wang found association with activatingKIR2DS1
in 73 RM patients within the Chinese Han population (Wang
et al. 2007). They also found decreased frequency of C2 +
HLA-C allotypes in affected patients compared to controls
(Wang et al. 2007). Because C2 + HLA-C allotypes are ex-
pected to bind KIR2DS1, it is difficult to draw a coherent
picture on the possible role of activating KIR2DS1 when the
ligand is missing. Faridi and Agrawal found increased fre-
quency of KIR2DS2 combined with C1 + HLA-C homozy-
gosity in both partners in a cohort of 177 North Indian RM
patients. In addition, they also found decreased frequency
of maternal KIR2DL1 as well as C2 + HLA-C homozy-
gosity in both partners in the RM group, suggesting
excessive activation of uNK cells may contribute to
RM (Faridi and Agrawal 2011).
Hiby et al. found thatKIR2DS1was underrepresented in 95
RM patients, and instead, the KIR AA genotype was more
frequent in the female partners of the affected couples (Hiby
et al. 2008). The finding that KIR AA genotypes were at the
expected frequency in the male partners of the affected cou-
ples was an informative internal control in this study. In addi-
tion, the frequency of C2 + HLA-C allotypes was increased in
both parents in the RM couples (Hiby et al. 2008). In accor-
dance with this, Alecsandru et al. found association with KIR
AA haplotype in 1304 IVF treatment cycles in 291 women
who experienced RM or recurrent implantation failure
(Alecsandru et al. 2014). However, HLA-C was not analysed
in this study. Although Dambaeva et al. did not confirm the
association of RM with increased KIR AA genotype or de-
creased KIR2DS1 frequency, they did find increased C2 +
HLA-C partners among the RM cases with KIR AA genotype
(Dambaeva et al. 2016). The scenario that emerges from these
three studies suggests that excessive inhibition of uNK cells
may be detrimental. In the study by Dambaeva et al., it was
also reported that C2 + HLA-C alleles were more frequent
within the KIR2DS1+ female partners of the RM couples
(Dambaeva et al. 2016). One interpretation is that NK cell
education may make the KIR2DS1+ decidual subset hypore-
sponsive, thus preventing its potentially beneficial contribu-
tion to maintenance of pregnancy. This would be consistent
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with a role for uNK cell education in preventing RM. As
initially conceived, the role of NK cell education through
inhbitory KIR may be to prime NK cells in resting state to
spring into action during MHC downregulation (missing–self
recognition). Missing-self recognition at the maternal-foetal
border, however, never occurs in pregnancy because EVT
always express one of the maternal HLA haplotype.
Moreover, >90% uNK cells express the inhibitory NKG2A
receptors that bind HLA-E on trophoblast. Therefore, if
and how inhibition during resting state (NK cell educa-
tion) benefits uNK cell effector functions during preg-
nancy is unknown. It is hard to directly compare these
studies on KIR and HLA association with RM because
they were done in different populations, and using dif-
ferent methodologies (Moffett and Hiby 2009).
KIR and HLA association with pre-eclampsia
Pre-eclampsia is an enigmatic and understudied disease that
only occurs in pregnancy and leads to preventable maternal
and perinatal deaths, particularly in Sub-Saharan Africa,
where the prevalence reaches 8–10% (Nakimuli et al. 2014).
Pre-eclampsia arises from a primary defect in placentation
leading to placental stress, triggering systemic decompensa-
tion of endothelial cells. The syndrome is characterized by a
range of clinical signs including high blood pressure, protein-
uria and edema (Redman and Sargent 2005). The UKNational
Health Service estimates that around 1000 children die each
year in the UK because of pre-eclampsia (NHS. Pre-eclampsia
2015). Pre-eclampsia occurs more often in first pregnancies,
with an incidence of 4.1% in nulliparous women decreasing to
1.7% in subsequent pregnancies. However, a history of pre-
eclampsia markedly predisposes to subsequent pregnancy
complications (van Oostwaard et al. 2015), with a risk of
recurrence of about 15 and 30 times higher after one or two
pregnancies with pre-eclampsia, respectively. This risk
reaches 30 and 60 after one or two pregnancies with severe,
early onset pre-eclampsia (Hernandez-Diaz et al. 2009). These
epidemiological and clinical data are consistent with two dis-
ease entities: a sporadic, milder form of pre-eclampsia ac-
counting for ~1% of all pregnancies and a recurrent, more
serious condition, accounting for 50–75% of cases in primip-
arous women.While the sporadic type may be due to transient
factors, such as twin pregnancies, the latter has more familial
aggregation, causes preterm birth and other maternal and foe-
tal morbidities, and it is probably affected by environmental
and genetic factors (Hernandez-Diaz et al. 2009). Pre-
eclampsia clusters within families and studies of concordance
in pre-eclamptic monozygotic twins suggest a genetic basis
for the pathogenesis of the disease (Chesley et al. 1968;
O'Shaughnessy et al. 2000). This, together with the observa-
tion of recurrent pre-eclampsia, suggest the involvement of
maternal genetic factors (Klungsoyr et al. 2012). The key role
of the placenta in the pathogenesis indicates that foetal genes
may also contribute. Indeed, genetic factors contribute tomore
than half the susceptibility to develop pre-eclampsia.
Maternal, foetal and couple genetics explained the variance
in susceptibility to pre-eclampsia (Cnattingius et al. 2004).
Uniquely among human diseases, therefore, interactions be-
tween maternal and foetal genotypes are important, and this
poses both challenges and opportunities in understanding the
pathogenesis of pre-eclampsia.
Association of KIR and HLAwith pre-eclampsia is perhaps
less controversial than with RM. Although an initial study
focussing on only one KIR gene, KIR2DL4, found no associ-
ation (Witt et al. 2002), Hiby et al., found that maternal KIR
AA genotypes and foetal C2 + HLA-C allotypes were more
frequent in the pre-eclampsia group. Subsequent studies by
the Moffett lab confirmed that the KIR AA genotype is over-
represented in pre-eclamptic pregnancies carrying C2 foetuses
in an extended UK cohort and in an independent Ugandan
cohort (Hiby et al. 2004, 2010; Nakimuli et al. 2015). Of note,
C2 + HLA-C allotypes are more frequent in Africans (Beziat
et al. 2017). Analysis of the parental origin of C2 indicated the
paternal HLA-C confers the risk (Hiby et al. 2010). This was
later substantiated by experiments showing that the important
receptors may be KIR2DL1 on the A haplotype and KIR2DS1
on B haplotypes, because both bind to C2+ HLA-C allotypes,
but one suppresses and the other elicits uNK cell responses
that may benefit placentation (Xiong et al. 2013). Importantly,
both KIR2DL1 and KIR2DS1 are expressed by large subsets
of uNK cells (Sharkey et al. 2008). One explanation for the
observed risk association with KIR AA and C2 is the greater
number of inhibitory KIR and the lack of activating KIR on
the KIR A haplotype. Moreover, a similar association was
found with FGR (Hiby et al. 2010) and birth weight (Hiby
et al. 2014). Evidence from mouse studies also suggests that
exaggerated uNK inhibition may be one key mechanism un-
derlying pregnancy complications (Kieckbusch et al. 2014).
On the other hand, haplotype B with KIR2DS1 is underrepre-
sented in pre-eclamptic pregnancies with C2+ HLA-C foe-
tuses and in pregnancies with high birth weight, suggesting
that active uNK cells may prevent pre-eclampsia and drive
foetal growth. KIR2DS4, present on tel-A in Caucasians, and
alleles of KIR2DS5, present on cen-B in Africans, are also
associated with resistance to pre-eclampsia (Nakimuli et al.
2014; Kennedy et al. 2016). These findings corroborate the
notion that activation of uNK cells enhances trophoblast inva-
sion, and leads to foetal growth (Moffett and Colucci 2014).
Another scenario, compatible with association of uNK cell
education with disease resistance emerged (Parham and
Guethlein 2010). Within the KIR AA pregnancies with C2+
HLA-C foetuses, women homozygous for C1 HLA-C were
more at risk than those carrying at least one C2 HLA-C allele.
This suggests that maternal C2+ HLA-C allotypes educate
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KIR2DL1+ uNK cells in resting state and counter the inhibi-
tory input of foetal C2+ HLA-C allotypes during pregnancy
(Hiby et al. 2010). However, differences in cell surface ex-
pression, binding strength and signalling functions of individ-
ual KIR alleles, as well as functional differences among HLA-
C alleles may confound the results (Beziat et al. 2017). Studies
in large cohorts that allow isolating the effect of alleles, in
combination with experiments that allow quantification of
uNK cell functions, will help to identify high-risk alleles.
Other interactions
Beyond the interactions between maternal KIR and foetal
HLA-C, others must be considered to appreciate the full pic-
ture (Ponte et al. 1999). Foetal HLA-G on trophoblast, for
example, can interact with uNK cells and monocytes through
KIR2DL4 and LILRB (Rajagopalan and Long 1999).
Moreover, the leader peptide of HLA-G is a powerful modifier
of HLA-E expression, and as such can modulate uNK cell
functions mediated by inhibitory NKG2A and activating
NKG2C. HLA-F has recently gained attention, as it can acti-
vate NK cells through binding KIR3DS1 (Burian et al. 2016;
Garcia-Beltran et al. 2016). While NKG2D and NKp46 may
activate uNK cells, 2B4 may be an important inhibitory recep-
tor as its signalling properties are specific to uNK cells (Vacca
et al. 2006), and the ligand is present at the maternal-foetal
interface (Apps et al. 2008). NKp30 and NKp44 too may
acquire decidual-specific signalling properties following ex-
pression of splice variants that make them key inhibitory re-
ceptors (Siewiera et al. 2015). The interactions between ma-
ternal KIR and maternal MHC class I molecules extend be-
yond HLA-C, because decidual cells express HLA-A and
HLA-B, and these may influence uNK cell education
(Sharkey et al. 2015).
Concluding remarks
On the wake of the recent success stories in immunology that
are changing clinical practice to treat patients with autoimmu-
nity and cancer, one may anticipate similar successes in other
areas of immunology. None of the studies on RM, however,
appears conclusive. The misconception that the maternal im-
mune system, including uNK cells, must be suppressed during
pregnancy, has led to the unsubstantiated view that activation
of uNK cells may drive some sort of foetal rejection. The
interpretation of some of the initial association studies with
RM seems influenced by this view. A large cohort study in a
homogeneous population, with a relevant control group and
standardized typing of maternal KIR and both maternal and
foetal HLA-C may shed more light on the role of KIR and
HLA in RM. More robust association has been shown of
certain combinations of maternal KIR and foetal HLA-C var-
iants, particularly the paternal HLA-C, with pre-eclampsia,
FGR and birth weight. Despite the compelling evidence, we
are still far from clinical applications (Moffett et al. 2016). For
example, the combination of the KIR AA genotype and foetal
C2 + HLA-C is found in about 10% of pregnant Caucasian
women. This combination exposes these pregnant women to a
risk of pre-eclampsia twice as great as that of the general
population. This is a significant risk; however, the predictive
power of the association is not clinically useful. Combining
this with other clinical and serological data may lead to gen-
erate algorithms that may yield a better predictive power. For
example, a new and elegant mathematical model predicts birth
weight based onKIR andHLA interactions (Clark et al. 2017).
We have learnt much about variability in KIR gene content,
polymorphism, inhibitory and activating receptors, variegated
expression, and we are learning about tissue-specific factors that
regulate NK cells. The major challenge is to tie together the
genetic data with the molecular mechanisms of disease (Beziat
et al. 2017). Moreover, we do not know the ligands for many
activating receptors, nor the role of trophoblast peptides in regu-
lating uNK cells. Also, it is very hard to pinpoint how exactly
KIR and HLA variants affect NK cell education and effector
functions. New technology may tackle the extreme diversity of
compound KIR and HLA genotypes. Refined lab assays may
help to better understand the biology of NK cells. For example,
we do not really know how to measure uNK cell responses
in vitro, and we rely on ‘proxy’ assays that measure cytokine
production and degranulation, which apply mostly to blood NK
cell functions. Intelligent use of mouse models could shed some
light on the immunogenetics of uNK cells and new transgenic
mice expressing specific KIR and HLA variants could help to
analyse the role of certain combinations in vivo. In 2005,
Rajagopalan and Long wrote in a commentary (Rajagopalan
and Long 2005): ‘Hopefully a molecular basis for the new dis-
ease associations with HLA– KIR gene combinations will be
provided before the year 2025’. They were referring to the
20 years or so that lapsed between the first disease association
with HLA polymorphism in the 1970s and the resolution of the
structure of the TCR bound to the MHCmolecules in the 1990s.
The challenge ahead is formidable, but we may be approaching
the objective and indeed, in some areas of medicine,
such as haematopoietic stem cell transplantation and
treatment of hepatitis, KIR typing is entering the clinical
practice and may improve patient outcome (Foley et al.
2014; Vidal-Castineira et al. 2014; Stelma et al. 2016).
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